DrugPatentWatch Database Preview

Ranbaxy Company Profile

« Back to Dashboard

What is the competitive landscape for RANBAXY, and when can generic versions of RANBAXY drugs launch?

RANBAXY has forty-five approved drugs.

There is one US patent protecting RANBAXY drugs. There are fifteen tentative approvals on RANBAXY drugs.

There are eighteen patent family members on RANBAXY drugs in eighteen countries and seventy-six supplementary protection certificates in fifteen countries.

Summary for Ranbaxy

International Patents:	18
US Patents:	1
Tradenames:	33
Ingredients:	29
NDAs:	45
Patent Litigation for Ranbaxy:	See patent lawsuits for Ranbaxy
PTAB Cases with Ranbaxy as petitioner:	See PTAB cases with Ranbaxy as petitioner

Drugs and US Patents for Ranbaxy

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ranbaxy Labs Ltd	PANIXINE DISPERDOSE	cephalexin	TABLET, FOR SUSPENSION;ORAL	065100-001	Sep 11, 2003		DISCN	No	No
Ranbaxy	RANITIDINE HYDROCHLORIDE	ranitidine hydrochloride	TABLET;ORAL	075254-001	Jan 14, 2000		DISCN	No	No
Ranbaxy Labs Ltd	CEFPROZIL	cefprozil	TABLET;ORAL	065198-002	Dec 13, 2006		DISCN	No	No
Ranbaxy	AVENTYL	nortriptyline hydrochloride	SOLUTION;ORAL	014685-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ranbaxy	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	040824-001	Aug 16, 2007		DISCN	No	No
Ranbaxy Labs Ltd	PANIXINE DISPERDOSE	cephalexin	TABLET, FOR SUSPENSION;ORAL	065100-002	Sep 11, 2003		DISCN	No	No
Ranbaxy Labs Ltd	CEFPROZIL	cefprozil	FOR SUSPENSION;ORAL	065202-002	Jun 30, 2006		DISCN	No	No

Expired US Patents for Ranbaxy

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ranbaxy	AVENTYL	nortriptyline hydrochloride	SOLUTION;ORAL	014685-001	Approved Prior to Jan 1, 1982	3,922,305

International Patents for Ranbaxy Drugs

Country	Patent Number	Estimated Expiration
Iceland	6709
Poland	365135
New Zealand	524519
Russian Federation	2003104808
Canada	2416767
Israel	154307
Australia	7659801

Supplementary Protection Certificates for Ranbaxy Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1506211	PA2014026	Lithuania		PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
1730131	C01730131/02	Switzerland		PRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
1412357	CA 2008 00035	Denmark		PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID
1506211	C300677	Netherlands		PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
1506211	300677	Netherlands		PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
0694547	2002/028	Ireland		PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Ranbaxy
• Ranbaxy Labs Ltd